Developmental changes in PON1 enzyme activity in young children and effects of PON1 polymorphisms

Environmental Health Perspectives

Volumn 117, Issue 10, 2009, Pages 1632-1638

  Huen, Karen ^a   Harley, Kim ^a   Brooks, Jordan ^a   Hubbard, Alan ^a   Bradman, Asa ^a   Eskenazi, Brenda ^a   Holland, Nina ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Age; Children; Enzymatic assay; Longitudinal birth cohort; Organophosphate metabolism; Oxidative stress; Paraoxonase; Pesticides; PON1 activity

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ORGANOPHOSPHATE PESTICIDE;

ADULT; AGE; ARTICLE; CHILD; CHILD DEVELOPMENT; COHORT ANALYSIS; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HISPANIC; HUMAN; INFANT; LONGITUDINAL STUDY; MALE; NEWBORN; NORMAL HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; TOXICOGENETICS; VULNERABLE POPULATION;

AGE FACTORS; ARYLDIALKYLPHOSPHATASE; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENOTYPE; HUMANS; INFANT; MALE; POLYMORPHISM, GENETIC;

EID: 70449565333     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.0900870     Document Type: Article

References (52)

1. Berkowitz GS, Wetmur JG, Birman-Deych E, Obel J, Lapinski RH, Godbold JH, et al. 2004. In utero pesticide exposure, maternal paraoxonase activity, and head circumference. Environ Health Perspect 112:388-391.
2. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, et al. 2008. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 299(11):1265-1276.
3. Brackley M, Carro-Ciampi G, Stewart DJ, Lowden JA, Ray AK, Kalow W. 1983. Stability of the paraoxonase phenotyping ratio in collections of human sera with differing storage times. Res Commun Chem Pathol Pharmacol 41(1):65-78.
4. Bradman A, Eskenazi B, Barr DB, Bravo R, Castorina R, Chevrier J, et al. 2005. Organophosphate urinary metabolite levels during pregnancy and after delivery in women living in an agricultural community. Environ Health Perspect 113:1802-1807. (Pubitemid 41794281)
5. Bradman A, Whitaker D, Quiros L, Castorina R, Henn BC, Nishioka M, et al. 2007. Pesticides and their metabolites in the homes and urine of farmworker children living in the Salinas Valley, CA. J Expo Sci Environ Epidemiol 17(4):331-349. (Pubitemid 47067417)
6. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE. 2001. Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet 68(6):1428-1436.
7. Chen D, Hu Y, Chen C, Yang F, Fang Z, Wang L, et al. 2004. Polymorphisms of the paraoxonase gene and risk of preterm delivery. Epidemiology 15(4):466-470.
8. Chen J, Kumar M, Chan W, Berkowitz G, Wetmur JG. 2003. Increased influence of genetic variation on PON1 activity in neonates. Environ Health Perspect 111:1403-1409. (Pubitemid 37063172)
9. Cole TB, Jampsa RL, Walter BJ, Arndt TL, Richter RJ, Shih DM, et al. 2003. Expression of human paraoxonase (PON1) during development. Pharmacogenetics 13(6):357-364. (Pubitemid 36724529)
10. Cole TB, Walter BJ, Shih DM, Tward AD, Lusis AJ, Timchalk C, et al. 2005. Toxicity of chlorpyrifos and chlorpyrifos oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism. Pharmacogenet Genomics 15(8):589-598. (Pubitemid 41044245)
11. Connelly PW, Maguire GF, Picardo CM, Teiber JF, Draganov D. 2008. Development of an immunoblot assay with infrared fluorescence to quantify paraoxonase 1 in serum and plasma. J Lipid Res 49(1):245-250.
12. Costa LG, Cole TB, Vitalone A, Furlong CE. 2005a. Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity. Clin Chim Acta 352(1-2):37-47. (Pubitemid 40093856)
13. Costa LG, Vitalone A, Cole TB, Furlong CE. 2005b. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 69(4):541-550.
14. Deakin SP, James RW. 2004. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci (Lond) 107(5):435-447.
15. Deakin SP, Leviev I, Brulhart-Meynet MC, James RW. 2003. Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position -107, implicating the Sp1 transcription factor. Biochem J 372(pt 2):643-649. (Pubitemid 36723911)
16. Department of Pesticide Regulation. 2005. Pesticide Use Report, Annual 2005. Sacramento, CA:Department of Pesticide Regulation, California Environmental Protection Agency.
17. Ecobichon DJ, Stephens DS. 1973. Perinatal development of human blood esterases. Clin Pharmacol Ther 14(1):41-47.
18. Erlich PM, Lunetta KL, Cupples LA, Huyck M, Green RC, Baldwin CT, et al. 2006. Polymorphisms in the PON gene cluster are associated with Alzheimer disease. Hum Mol Genet 15(1):77-85. (Pubitemid 43020106)
19. Eskenazi B, Bradman A, Gladstone E, Jaramillo S, Birch K, Holland N. 2003. CHAMACOS, a longitudinal birth cohort study: lessons from the fields. J Childrens Health 1:3-27.
20. Eskenazi B, Harley K, Bradman A, Weltzien E, Jewell NP, Barr DB, et al. 2004. Association of in utero organophosphate pesticide exposure and fetal growth and length of gestation in an agricultural population. Environ Health Perspect 112:1116-1124.
21. Eskenazi B, Rosas LG, Marks AR, Bradman A, Harley K, Holland N, et al. 2008. Pesticide toxicity and the developing brain. Basic Clin Pharmacol Toxicol 102(2):228-236.
22. Ferre N, Camps J, Fernandez-Ballart J, Arija V, Murphy MM, Ceruelo S, et al. 2003. Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population. Clin Chem 49(9):1491-1497.
23. Furlong CE, Cole TB, Jarvik GP, Costa LG. 2002. Pharmacogenomic considerations of the paraoxonase polymorphisms. Pharmacogenomics 3(3):341-348.
24. Furlong CE, Cole TB, Jarvik GP, Pettan-Brewer C, Geiss GK, Richter RJ, et al. 2005. Role of paraoxonase (PON1) status in pesticide sensitivity: genetic and temporal determinants. Neurotoxicology 26(4):651-659.
25. Furlong CE, Holland N, Richter RJ, Bradman A, Ho A, Eskenazi B. 2006. PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity. Pharmacogenet Genomics 16(3):183-190. (Pubitemid 43312580)
26. Garces C, Lopez-Simon L, Rubio R, Benavente M, Cano B, Ortega H, et al. 2008. High-density lipoprotein cholesterol and paraoxonase 1 (PON1) genetics and serum PON1 activity in prepubertal children in Spain. Clin Chem Lab Med 46(6):809-813. (Pubitemid 351821638)
27. Holland N, Furlong C, Bastaki M, Richter R, Bradman A, Huen K, et al. 2006. Paraoxonase polymorphisms, haplotypes, and enzyme activity in Latino mothers and newborns. Environ Health Perspect 114:985-991. (Pubitemid 44018892)
28. Hox J. 2002. Multilevel Analysis: Techniques and Applications. Mahwah, NJ:Lawrence Erlbaum Associates.
29. Huen K, Richter R, Furlong C, Eskenazi B, Holland N. 2009. Validation of PON1 enzyme activity assays for longitudinal studies. Clin Chim Acta 402(1-2):67-74.
30. James RW. 2006. A long and winding road: defining the biological role and clinical importance of paraoxonases. Clin Chem Lab Med 44(9):1052-1059.
31. James RW, Kalix B, Bioletto S, Brulhart-Meynet MC. 2005. Paraoxonase-1 promoter polymorphism C-107T and serum apolipoprotein AI interact to modulate serum paraoxonase-1 status. Pharmacogenet Genomics 15(6):441-446. (Pubitemid 40835087)
32. Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD, et al. 2000. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol 20(11):2441-2447.
33. Karikas GA, Kriebardis A, Samara I , Schulpis K, Papachristodoulou M, Fytou-Pallikari A. 2006. Serum homocysteine levels and paraoxonase 1 activity in pre-school aged children in Greece. Clin Chem Lab Med 44(5):623-627. (Pubitemid 43735637)
34. Kujiraoka T, Oka T, Ishihara M, Egashira T, Fujioka T, Saito E, et al. 2000. A sandwich enzyme-linked immunosorbent assay for human serum paraoxonase concentration. J Lipid Res 41(8):1358-1363. (Pubitemid 30666902)
35. Lawlor DA, Gaunt TR, Hinks LJ, Davey Smith G, Timpson N, Day IN, et al. 2006. The association of the PON1 Q192R polymorphism with complications and outcomes of pregnancy: findings from the British Women's Heart and Health cohort study. Paediatr Perinat Epidemiol 20(3):244-250.
36. Li HL, Liu DP, Liang CC. 2003. Paraoxonase gene polymorphisms, oxidative stress, and diseases. J Mol Med 81(12):766-779. (Pubitemid 38058159)
37. Li WF, Costa LG, Richter RJ, Hagen T, Shih DM, Tward A, et al. 2000. Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 10(9):767-779. (Pubitemid 32042829)
38. Moser VC, Chanda SM, Mortensen SR, Padilla S. 1998. Age- and gender-related differences in sensitivity to chlorpyrifos in the rat reflect developmental profiles of esterase activities. Toxicol Sci 46(2):211-222. (Pubitemid 29069605)
39. Parker-Katiraee L, Bousiaki E, Monk D, Moore GE, Nakabayashi K, Scherer SW. 2008. Dynamic variation in allele-specific gene expression of Paraoxonase-1 in murine and human tissues. Hum Mol Genet 17(21):3263-3270.
40. R Development Core Team. 2008. R: A Language and Environment for Statistical Computing. Vienna, Austria:R Foundation for Statistical Computing.
41. Rainwater DL, Rutherford S, Dyer TD, Rainwater ED, Cole SA, Vandeberg JL, et al. 2008. Determinants of variation in human serum paraoxonase activity. Heredity 102(2):147-154.
42. Richter RJ, Furlong CE. 1999. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 9(6):745-753.
43. Rojas-Garcia AE, Solis-Heredia MJ, Pina-Guzman B, Vega L, Lopez-Carrillo L, Quintanilla-Vega B. 2005. Genetic polymorphisms and activity of PON1 in a Mexican population. Toxicol Appl Pharmacol 205(3):282-289. (Pubitemid 40726303)
44. Seres I, Paragh G, Deschene E, Fulop T Jr, Khalil A. 2004. Study of factors influencing the decreased HDL associated PON1 activity with aging. Exp Gerontol 39(1):59-66. (Pubitemid 38068260)
45. Stenzel J, Worek F, Eyer P. 2007. Preparation and characterization of dialkylphosphoryl-obidoxime conjugates, potent anticholinesterase derivatives that are quickly hydrolyzed by human paraoxonase (PON1192Q). Biochem Pharmacol 74(9):1390-1400. (Pubitemid 47445445)
46. Sumegova K, Nagyova Z, Waczulikova I, Zitnanova I, Durackova Z. 2007. Activity of paraoxonase 1 and lipid profile in healthy children. Physiol Res 56(3):351-357.
47. Timchalk C, Kousba AA, Poet TS. 2007. An age-dependent physiologically based pharmacokinetic/pharmacodynamic model for the organophosphorus insecticide chlorpyrifos in the preweanling rat. Toxicol Sci 98(2):348-365. (Pubitemid 47244808)
48. Vincent-Viry M, Sass C, Bastien S, Aguillon D, Siest G, Visvikis S. 2003. PON1-192 phenotype and genotype assessments in 918 subjects of the Stanislas cohort study. Clin Chem Lab Med 41(4):535-540. (Pubitemid 36592121)
49. Wolff MS, Engel S, Berkowitz G, Teitelbaum S, Siskind J, Barr DB, et al. 2007. Prenatal pesticide and PCB exposures and birth outcomes. Pediatr Res 61(2):243-250. (Pubitemid 46146885)
50. Young JG, Eskenazi B, Gladstone EA, Bradman A, Pedersen L, Johnson C, et al. 2005. Association between in utero organophosphate pesticide exposure and abnormal reflexes in neonates. Neurotoxicology 26(2):199-209.
51. Zemke AC, Snyder JC, Brockway BL, Drake JA, Reynolds SD, Kaminski N, et al. 2009. Molecular staging of epithelial maturation using secretory cell-specific genes as markers. Am J Respir Cell Mol Biol 40(3):340-348.
52. Zintzaras E, Hadjigeorgiou GM. 2004. Association of paraoxonase 1 gene polymorphisms with risk of Parkinson's disease: a meta-analysis. J Hum Genet 49(9):474-481. (Pubitemid 39314366)